Full-Time

Quality Engineer 2

Posted on 2/26/2025

Natera

Natera

1,001-5,000 employees

Biotechnology firm specializing in genetic testing

Compensation Overview

$77.2k - $96.4k/yr

Mid, Senior

Company Historically Provides H1B Sponsorship

San Carlos, CA, USA

Remote work is available for candidates based in the USA.

Category
QA & Testing
Quality Assurance
Requirements
  • B.S. or equivalent in science, engineering or related field
  • At least 4 years of experience in medical diagnostic, CLIA laboratory, or Life Sciences industry
  • 2 years experience working in a Quality role preferred
  • Audit experience – internal audits, third party audits and/or regulatory audits
  • American Society of Quality certifications (CQE) preferred
Responsibilities
  • Support internal and external audits (CLIA/CAP, ISO 13485, customer)
  • Support CAPA, Deviation, Change Requests and Nonconformance investigation and reporting
  • Write/revise procedures and forms
  • Perform statistical analysis/hypotheses testing (AQL’s etc) as required
  • Support Quality systems compliance to CLIA, FDA QSR, ISO 13485, and HIPAA
  • Participate in the management of Approved Suppliers
  • Follow established company standard operating procedures and good documentation practices
  • Review manufacturing/QC batch records
  • Other duties as assigned
Desired Qualifications
  • Knowledge of CLIA/CAP regulations, ISO 13485 standard and/or FDA QSRs (21 CFR 820)
  • Computer skills (MS Word, Excel, PowerPoint, etc.)
  • Good technical writing and communication skills
  • Independent worker, a self-starter with strong organizational and planning skills
  • Hands on experience with DNA Isolation and Purification, PCR, Cell Culture, Sequencing, Bioinformatics etc.

Natera specializes in genetic testing and diagnostics within the healthcare sector, offering advanced testing solutions for cancer patients, transplant patients, and individuals assessing hereditary health risks. The company utilizes cell-free DNA (cfDNA) testing to analyze DNA fragments in the blood, which helps detect minimal traces of cancer after treatment, guiding treatment decisions. One of their key products is the Signatera test, a custom ctDNA test for cancer patients, available through a remote access program. Natera also provides testing for organ health in transplant patients and offers a variety of tests for women's health, including the Panorama NIPT for prenatal screening. Their business model focuses on selling testing kits and services to healthcare providers and patients, often with insurance reimbursement. Natera distinguishes itself by combining specialized testing with genetic counseling services, allowing patients to receive personalized guidance remotely.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Austin, Texas

Founded

2004

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased AI adoption in genetic testing enhances Natera's prenatal and cancer diagnostics.
  • Remote healthcare trends expand the market for Natera's at-home genetic testing kits.
  • Advancements in liquid biopsy technologies benefit Natera's market reach and accessibility.

What critics are saying

  • Increased competition from companies like Lantheus Holdings may impact Natera's market share.
  • The sale of company stock by Natera's CFO might indicate potential internal concerns.
  • Adoption challenges for the Donor Quantity Score in Prospera Heart could affect its success.

What makes Natera unique

  • Natera specializes in cell-free DNA testing for prenatal and cancer diagnostics.
  • The company offers unique tests like Signatera and Prospera Heart with Donor Quantity Score.
  • Natera provides remote genetic counseling, enhancing accessibility for patients.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible medical plans

Investment options

Time off

Workplace perks

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

5%
Slater Sentinel
Apr 3rd, 2025
DnB Asset Management AS Invests $235,000 in Natera, Inc. (NASDAQ:NTRA)

DnB Asset Management AS invests $235,000 in Natera, Inc. (NASDAQ:NTRA).

TXBN
Mar 25th, 2025
DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting

AUSTIN, Texas - (BUSINESS WIRE) - Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced that it will share results from the DEFINE-HT study in a late-breaking oral presentation at the International Society for Heart and Lung Transplantation (ISHLT) 45th Annual Meeting on April 29, 2025.

Simply Wall St
Mar 13th, 2025
Natera (NasdaqGS:NTRA) Welcomes Former National Cancer Institute Director Back to Board

Last week, Natera (NasdaqGS:NTRA) announced a strategic expansion of its Board of Directors with the appointment of Monica Bertagnolli.

Investing.com
Mar 10th, 2025
Natera launches HEROES trial for breast cancer treatment

Natera launches HEROES trial for breast cancer treatment.

Financial Modeling Prep
Feb 28th, 2025
Lantheus Holdings, Inc. (NASDAQ:LNTH) Demonstrates Strong Capital Efficiency

Lantheus competes with other companies in the medical and pharmaceutical industries, such as ShockWave Medical, Medpace Holdings, LivaNova, Apellis Pharmaceuticals, and Natera.

INACTIVE